Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Imatinib and Pegylated Interferon-a 2B in Imatinib-naïve Gastrointestinal Stromal Tumor (GIST) Patients
This study has been terminated.
( Data Safety Monitoring Committee decision )
Study NCT00585221   Information provided by University of Utah
First Received: December 21, 2007   Last Updated: July 17, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Additional conditions recognized in this trial
Gastrointestinal Stromal Tumors
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Site
Interventions listed in this trial
Pegylated Interferon-a 2B
Additional drug interventions recognized in this trial
Imatinib
Interferon Alfa-2b
Interferon-alpha
Interferons
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
University of Utah


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services